Hit ID Platform

Banner Image

At the core of a successful drug discovery is a high-quality chemical library. A fit-for-purpose drug discovery library is not a random collection of compounds, but a collection of carefully curated chemistry that is designed to cover the diversity of drug-like chemistry space, and provide tractable starting points for medicinal chemistry optimisation.

This project will build on a national framework to provide Australian drug discovery organisations access to a comprehensive Hit ID platform that includes:

  • a fit for purpose drug discovery library (up to 300,000 compounds);
  • an ultra-high throughput screening facility;
  • fragment-based drug design capability;
  • a state of the art software platform for in silico drug discovery.

Outcomes: Working copies of the ALIDC library (315,000 compounds) have been stored at Compounds Australia and used for more than 15 projects by teams at the member institutes. A complete reformat of the library is underway to generate focused library sub-sets and facilitate accessibility by the wider research community.

    Consortium lead

    Cancer Therapeutics CRC Pty Ltd (CTx)

    Consortium members

    UniQuest, Walter and Eliza Hall Institute (WEHI), Children's Cancer Institute (CCI), Griffith University / Compounds Australia

    MTPConnect grant $1,100,000
    Industry contribution $2,044,302
    Project duration August 2017 - June 2019 (Finished)
    Contact Brendon Monahan, Cancer CRC - brendon@cancercrc.com

    Visit Cancer Therapeutics CRC for more details  |  Twitter: cancercrc & GRIDD_GU  |  LinkedIn: Cancer Therapeutics CRC